Accurate and efficient matching of individual patients to their health records across settings is a wonderful thing if we can do it right.

I think we are all better informed of the complexity of the issues involved.

I have heard from many providers and vendors, both large and small, about some of the challenges in becoming 'meaningful users'.

In light of the current expectation that almost every eligible professional and hospital will need to upgrade in order to comply with Stage 2 requirements, is the vendor community adequately resourced to meet this unprecedented demand for…

Incorrectly matching a patient to a health record may have patient safety, privacy, and security implications.

EPA's recent announcement that it is walking away from its attempt to link hydraulic fracturing to groundwater issues in Wyoming is the most recent example of the Agency employing what I consider a 'shoot first, ask questions later' policy…

The Agency should base its work on sound science rather than regulatory ambition.

But to the extent that the existence of the patent and the existence of the current patent term as we have it set up, facilitates innovation, leads to innovation.

Pharmaceutical patents are extremely valuable and it's for good reason that they're valuable.

Opponents of reverse settlements have for several years argued that they're anti-competitive.

Both this recoupment of investment and these profits are jeopardized by lawsuits that are filed by generics.

Proponents of the agreements have argued that the agreements can never properly be considered anti-competitive.

I agree with the holding of the Supreme Court.

But to assume that requires us to assume at the outset that the patent is, in fact, invalid.

On average, it takes 10 years and $1 billion to develop and gain FDA approval for a new drug.

I want to talk just a little bit about our use of the term 'pay for delay' today.

Wouldn't you have to concede that then in that circumstance you've got pro-competitive effects?

Some brand-name manufacturers have chosen to settle lawsuits filed by generics instead of litigating.